Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364861 | 1.00 | CTSL (0.49) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364435 | 0.96 | CTSL (0.46) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364315 | 0.96 | CTSL (0.46) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364849 | 0.88 | NPC1 (0.50) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364860 | 0.88 | NPC1 (0.50) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364857 | 0.87 | CTSL (0.47) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364863 | 0.87 | CTSL (0.47) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364847 | 0.86 | CTSL (0.46) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364866 | 0.86 | CTSL (0.46) | CTSLNPC1RAB9APIN1HCAR2 | |
| SCHEMBL18364862 | 0.85 | ROCK2 (0.50) | CTSLPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008834-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008834-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008834-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | CTSL 2900/4885NPC1 2073/4885RAB9A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.